MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

KEY TAKEAWAYS French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, ...

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

The French pharmaceutical giant is acquiring a Cambridge biotech and its rare immunology disease which is already approved in ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season  Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early ...

Global Employee Stock Purchase Plan  Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th ...

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...